Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:05:36.070Z.
Consensus retrieved: 2026-10-06T08:51:00.409Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:05:36.070Z.
Quote observation: 2026-10-06T15:05:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 66e3eaee1cdd755dffe0dd2f4d89b3fc137545160e5faabf240127d9674bae42
Forward PE Ratio (N/A) = Dated Quote Price ($5.26) / Consensus Forward EPS ($-0.89)
FORWARD PE RATIO
N/A
AN2 Therapeutics, Inc.
Market Cap
$189.45M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $189.45M | N/A |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $192.58M | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $182.53M | 1.00 |
| Canton Strategic Holdings Inc (CNTN)vs › | $181.62M | N/A |
| Electra Therapeutics Inc. (ETRA)vs › | $198.76M | N/A |
| Journey Medical Corporation (DERM)vs › | $179.09M | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $178.38M | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $175.00M | N/A |
| MediWound Ltd. (MDWD)vs › | $172.90M | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $172.79M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $5.26, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.90 | $-0.90 – $-0.90 | 1 | n/m |
| 2027-12-31 | $-0.80 | $-0.80 – $-0.80 | 1 | n/m |
| 2028-12-31 | $-0.82 | $-0.82 – $-0.82 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
